Recruiting
Phase 3

Etentamig & Pomalidomide

Sponsor:

AbbVie

Code:

NCT07728188

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Etentamig

Pomalidomide

Daratumumab

Dexamethasone

Carfilzomib

Study Details

Brief summary:

Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide.

Etentamig is an investigational drug being developed for the treatment of relapsed or refractory multiple myeloma. This is a randomized, open-label study. The study will include a safety run-in portion and a randomized portion. The safety run-in participants will receive etentamig in combination with pomalidomide. The randomized portion of the study participants will receive either etentamig with pomalidomide or Standard Available Therapies (SATs). Approximately 520 participants will be enrolled in the study at approximately 200 sites worldwide.

Prior to initiation of the randomized portion of the study, the safety run-in will be conducted in which participants will receive etentamig injections plus oral pomalidomide. Following review of the safety run-in data and per protocol-defined criteria, the study will advance to the randomized portion where participants will be randomized to receive either etentamig injections plus oral pomalidomide or investigator's choice of SAT: SC daratumumab, oral pomalidomide, and oral/ IV dexamethasone (DPd); SC daratumumab, IV carfilzomib, and oral/IV dexamethasone (DKd); or SC teclistamab monotherapy. The total study duration is approximately 75 months

There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

Relapsed or Refractory Multiple Myeloma

Study ID

NCT07728188

Start date

Oct 20, 2026

Status verified date

Nov, 2026

Completion date

Feb, 2033

Anticipated

Primary completion date

Feb, 2033

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of relapsed or refractory (RR) multiple myeloma (MM).
  • Prior treatment with at least one and no more than three prior lines of therapy, including lenalidomide.
  • Adequate organ function and performance status

Exclusion Criteria:

  • Prior B-cell maturation antigen (BCMA) directed T-cell engager therapy (bispecific or trispecific)
  • Known central nervous system involvement of MM
  • Known history of other active malignancies within the past 3 years (with specific exceptions)
  • Clinically significant conditions (renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, pulmonary, or hepatic disease within the last 6 months)

Study Design

Enrollment

520 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Safety Run-In: Etentamig Plus Pomalidomide

Participants will receive etentamig in combination with pomalidomide, as part of the approximately 75 month study duration.

experimental: Randomized Portion: Etentamig Plus Pomalidomide

Participants will receive etentamig in combination with pomalidomide, as part of the approximately 75 month study duration.

active comparator: Randomized Portion: Standard Available Therapy (SAT)

Participants will receive Investigator's choice of SATs: DPd, DKd, or teclistamab monotherapy as part of the 75 month study duration.

Interventions

Etentamig

Injection

Pomalidomide

Oral

Daratumumab

Injection

Dexamethasone

Oral or Injection

Carfilzomib

Injection

Teclistamab

Injection

Primary outcome measure

  • Safety Run-In: Number of Participants With Adverse Events (AE)s [ Time Frame: Up to Approximately 75 Months ]
  • Randomized Portion: Complete Response (CR) or Better Rate Per Independent Review Committee (IRC) Assessment [ Time Frame: Up to Approximately 75 Months ]
  • Randomized Portion: Progression-Free Survival (PFS) Per Independent Review Committee (IRC) Assessment [ Time Frame: Up to Approximately 75 Months ]

Central Contacts and Locations

Central contacts

Locations

Community Cancer Trials Of Utah /ID# 286936

Recruiting

Ogden, Utah, United States, 84405

More Information

Sponsor

AbbVie

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Keywords

  • Relapsed or Refractory Multiple Myeloma
  • Etentamig
  • Pomalidomide
  • Cancer

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by AbbVie on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.